Proxy Biomedical Ltd., Galway, is adding 3000-ft2 of additional cleanroom space rated to Class 8/ 100,000 to support production of new products, according to a company spokesperson, a move that effectively doubles its cleanroom manufacturing space. Proxy declined to reveal the total amount of investment.
Among the products launched in 2015 which are prompting the expansion are resorbable and non-resorbable biomaterials for vascular indication; Proxy Bio-XT, a proprietary process that reinforces resorbable implants for applications including soft tissue fixation in orthopaedics; and ProTEX Med polypropylene, a custom synthesized resin with a FDA Master File reference.
Proxy’s plastics processing capabilities include compression molding, injection molding, lamination and multi-axial laser processing. The company also has what it describes as a number of systems for resorbable polymer material quality control and characterization.